Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: A model framework

American Health and Drug Benefits

Volumn 8, Issue 4, 2015, Pages 204-214

  Roy, Anuja ^a   Kish, Jonathan K ^b   Bloudek, Lisa ^b   Siegel, David S ^c   Jagannath, Sundar ^d   Globe, Denise ^a   Kuriakose, Emil T ^a   Migliaccio Walle, Kristen ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Xcenda   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d MOUNT SINAI HOSPITAL   (United States)

Author keywords

Costs; Histone deacetyl ase inhibitor; Immunomodulatory drug; Model framework; Progression free survival; Proteasome inhibitor; Relapsed refractory multiple myeloma

Indexed keywords

ACICLOVIR; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE; PANOBINOSTAT; POMALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; CANCER RECURRENCE; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG MONITORING; DYSPNEA; ELECTROCARDIOGRAPHY; FEBRILE NEUTROPENIA; FEMALE; HEART FIBRILLATION; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MEDICARE; MIDDLE AGED; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

EID: 84932621745     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301-318.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): multiple myeloma. Version 4.2015. www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed March 15, 2015.
3. Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010;21(suppl 7):vii143-vii150.
4. National Cancer Institute. SEER stat fact sheets: myeloma. http://seer.cancer.gov/statfacts/html/mulmy.html. Accessed March 15, 2015.
5. Rajkumar SV, Harousseau JL, Durie B, et al For the International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691-4695.
6. Madan S, Lacy M, Dispenzieri A, et al. Efficacy of retreatment with immu-nomodulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 1964.
7. Petrucci MT, Giraldo P, Corradini P, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013;160:649-659.
8. Kim Y, Schmidt-Wolf IG. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2015;15:491-497.
9. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867-874.
10. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘re-treatment’ approaches in the era of novel agents. Leukemia. 2012;26:73-85.
11. National Cancer Institute. Cancer trends progress report–2011/2012 update. August 22, 2014. http://progressreport.cancer.gov/sites/default/fles/archive/report2011.pdf. Accessed March 15, 2015.
12. Cook R. Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm. 2008;14(7 suppl):S19-S25.
13. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109:2334-2342.
14. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-1128.
15. Durie B, Binder G, Pashos C, et al. Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ. 2013;16:614-622.
16. Elixhauser A, Steiner C. Readmissions to U.S. hospitals by diagnosis, 2010. Statistical brief #153. April 2013. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality (US). www.hcup-us.ahrq.gov/reports/statbriefs/sb153.pdf. Accessed March 15, 2015.
17. Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18:37-45.
18. Anhang Price R, Stranges E, Elixhauser A. Cancer hospitalizations for adults, 2009. Statistical brief #125. February 2012. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Healthcare Research and Quality (US). www.hcup-us.ahrq.gov/reports/statbriefs/sb125.pdf. Accessed March 15, 2015.
19. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259-2266.
20. Petrucci T, Blau I, Corradini P, et al. Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: interim results from RETRIEVE, a prospective international phase 2 study. Haematologica. 2010;95 (suppl 2). Abstract 0377.
21. Messori A, Maratea D, Nozzoli C, Bosi A. The role of bortezomib, thalido-mide and lenalidomide in the management of multiple myeloma: an overview of clincial and economic information. Pharmacoeconomics. 2011;29:269-285.
22. San-Miguel JF, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezo-mib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multi-centre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195-1206. Erratum in: Lancet Oncol. 2015;16:e6.
23. Farydak (panobinostat) capsules [prescribing information]. East Hanover, NJ: Novartis; February 2015.
24. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147-2152.
25. Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123:1461-1469.
26. Stewart AK, Rajkumar SV, Dimopoulos MA, et al For the ASPIRE Investigators. Carflzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152.
27. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent car-flzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817-2825.
28. Pomalyst (pomalidomide) capsules [prescribing information]. Summit, NJ: Celgene Corporation; April 2015.
29. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexa-methasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055-1066.
30. RED BOOK Online. Truven Health Analytics; 2015. www.redbook.com/redbook/online/. Accessed March 15, 2015.
31. Centers for Medicare & Medicaid Services. Payment allowance limits for Medicare Part B drugs: effective January 1, 2015 through March 31, 2015. www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles.html. Accessed January 26, 2015.
32. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy. March 2014. www.medpac.gov/documents/reports/mar14_entirereport.pdf?sfvrsn=0. Accessed October 21, 2014.
33. US Bureau of Labor Statistics. Consumer Price Index. www.bls.gov/cpi/. Accessed March 15, 2015.
34. Binder G, Harwin WN, Stemkowski S, et al. Drug resource use and costs for novel agents in multiple myeloma. J Clin Oncol. 2012;30(15 suppl). Abstract e18560.
35. Anderson KC, Kyle RA, Rajkumar SV, et al For the ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22:231-239.
36. Niesvizky R, Richardson PG, Rajkumar SV, et al. The relationship between quality of response and clinical beneft for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143:46-53.
37. Lonial S, Roy A, Globe D, et al. Estimating cost per month of progression free survival (PFS) from a payer perspective: comparing commonly used treatment regimens for previously treated relapsed and/or refractory multiple myeloma (RRMM). Presented at: Academy of Managed Care Pharmacy 2015 Annual Meeting & Expo; April 7-10, 2015; San Diego, CA. Abstract D6.
38. Petrucci MT, Finsinger P, Chisini M, Gentilini F. Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefts. Patient Prefer Adherence. 2014;8:939-946.
39. Acaster S, Gaugris S, Velikova G, et al. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. Support Care Cancer. 2013;21:599-607.
40. Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 2010;116:3743-3750.
41. Madan S, Lacy MQ, Dispenzieri A, et al. Efficacy of retreatment with im-munomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood. 2011;118:1763-1765.